Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
NCT01623167Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2012
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in aplastic anemia, sponsored by National Heart, Lung, and Blood Institute. Started Jul 2012; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT01623167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01623167.